The sCD13 protein has been previously identified by a rheumatology research team at the University of Michigan as a powerful ...

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, ...

DelveInsight's " Aplastic Anemia Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth ...

FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

Some people may be more vulnerable to infections and illnesses than others and several factors can be to blame Here’s what a ...

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular ...